N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
N/A N=17,108 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Lymphatic Filariasis · Soil Transmitted Helminth Infections
Primary: Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood — 54; 36; 146; 46 Participants
Phase 3 N=164 Moxidectin for LF, Cote d'Ivoire (DOLF)
Lymphatic Filariasis
Primary: Clearance of Microfilaremia (IA vs. MoxA) — 8; 18; 24; 27 Participants
Phase 2 N=8 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Loiasis
Primary: Peak Eosinophil Count Post-treatment — 61; 245.6 percent of baseline eosinophil count — p=0.028
Phase 4 N=12 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Loiasis
Primary: The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment. — 196; 165 percentage of baseline — p=0.68
Phase 4 N=41 Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Loiasis
Primary: Cross-reactive Antigenemia — 12 Participants
Phase 3 N=356,912 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Helminthiasis · Filariasis
Primary: Comparison of Arms - Benin — 322; 748; 11; 11 Participants
Phase 3 N=12,979 Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Onchocerciasis
Primary: Incidence and Severity of Treatment Emergent Adverse Events — 346; 79; 1199; 288 participants
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
Phase 3 N=223 Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Observed Cure Rate Against Strongyloides Stercoralis — 73.3; 89.7; 84.4; 82.8 percentage of participants
Phase 2 N=154 Safety and Efficacy of IDA for Onchocerciasis
Onchocerciasis
Primary: Rates of Severe Adverse Events (SAEs) Across Study Arms — 0; 0; 0 Participants
Phase 4 N=50 Lymphedema Study for Arm or Leg Lymphedema
Lymphedema
Primary: Part 1: Count of Participants Able to Complete Ketoprofen Treatment — 50 Participants